Birociclib monotherapy is used to treat adult patients with locally advanced or metastatic HR+ or HER2- breast cancer who have previously received two or more endocrine therapies and one chemotherapy and have experienced disease progression [74]. This evidence concerns the gene ERBB2 and breast carcinoma.